What were the results of the ENERGY trial?

The Phase 2/3 ENERGY trial showed statistically significant improvement in hemoglobin levels in patients treated with IMAAVY versus placebo.

Is there an FDA-approved treatment for wAIHA currently?

No, there is currently no FDA-approved treatment for warm autoimmune hemolytic anemia.

When does Johnson & Johnson expect to file for approval?

The company has not specified a date but expects to file an FDA application later this year.

Johnson & Johnson Reports Positive Late-Stage Results for Rare Blood Disorder Drug

Johnson & Johnson announced positive results from its Phase 2/3 ENERGY clinical trial for IMAAVY (nipocalimab-aahu) in warm autoimmune hemolytic anemia, demonstrating statistically significant hemoglobin improvement versus placebo. The therapy targets a condition with no FDA-approved treatments.

June 11, 2026

2 min read

Source: InvestorsHub

Key Numbers

trial phase

2/3

hemoglobin improvement

statistically significant

Johnson & Johnson (NYSE:JNJ) announced positive results from its Phase 2/3 ENERGY clinical trial, with IMAAVY (nipocalimab-aahu) showing statistically significant improvements in hemoglobin levels among patients with warm autoimmune hemolytic anemia (wAIHA) compared to placebo. The results support regulatory filing for a condition that currently has no FDA-approved treatment.

The Product

IMAAVY (nipocalimab) is a monoclonal antibody targeting the FcRn receptor, reducing circulating IgG antibody levels. Administered intravenously every two weeks, it has demonstrated efficacy in raising hemoglobin and reducing transfusion needs.

Pricing and Availability

Johnson & Johnson has not yet disclosed pricing or a specific timeline for regulatory submission. An FDA application is expected later this year.

Competition

No FDA-approved therapy currently exists for wAIHA, giving IMAAVY a potential first-to-market advantage. However, competitors such as UCB's rozanolixizumab are also in development.

Potential Impact on JNJ

This therapy represents a significant opportunity in the rare disease market, with wAIHA incidence estimated at 1-3 per 100,000 annually. Success could bolster JNJ's pharmaceutical segment revenues.

Frequently Asked Questions

IMAAVY (nipocalimab) is a monoclonal antibody targeting the FcRn receptor to reduce IgG antibody levels, administered intravenously for warm autoimmune hemolytic anemia.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.